La vendita allo scoperto per Olema Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Olema Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Olema Pharmaceuticals (NASDAQ:OLMA) Azioni, Report sulle vendite allo scoperto

Olema Pharmaceuticals

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals inc

Susquehanna analyst Christopher Rolland maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Positive and lowers the price target from $160 to $135.

News

Price Target

Analyst Ratings

CRUS

Susquehanna Maintains Positive on Cirrus Logic, Lowers Price Target to $135

WIIM

PAYO

Payoneer Global shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its FY24 revenue guidance.

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is up 3.7% over the past 24 hours as positive news from its <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">community bolster sentiment</a>.
What Happened: Pseudonymous lead developer Shytoshi Kusama <a href="https://blog.shib.io/strategic-hub-for-innovation-in-blockchain/">suggested</a> establishing a blockchain innovation hub in the U.S., inviting presidential candidates to endorse a "Silicon Valley" for the blockchain sector.  
This initiative, dubbed S.H.I.B., aims to drive economic growth, create quality jobs, and reinforce the U.S. as a leader in emerging technologies. Kusama estimated the project cost at $1.3 to $2.35 billion over 5-10 years.
By leveraging blockchain&#8217;s transformative potential, this S.H.I.B. initiative aims to stimulate economic growth, create high-quality jobs, enhance national security, and reinforce the United States&#8217; leadership in emerging technologies.
Crypto analyst Javon Marks reaffirmed his target price of $0.000081 for SHIB, suggesting the meme coin may be entering its next growth phase.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> (Shiba Inu) remains broken out and has confirmed a bull pattern with the RSI on the daily chart! Overall Target is still at $0.000081 and the next leg towards it can be in early stages, initiated by the falling wedge breakout&#8230; <a href="https://t.co/pbBS66quWM">https://t.co/pbBS66quWM</a> <a href="https://t.co/MVu7lBfoqG">pic.twitter.com/MVu7lBfoqG</a>
&mdash; JAVON&#x26a1;&#xFE0F;MARKS (@JavonTM1) <a href="https://twitter.com/JavonTM1/status/1853599365069472037?ref_src=twsrc%5Etfw">November 5, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Last week, trader Investing Haven noted that Shiba Inu "avoided" the forecasted drop in October thereby implying "strong buying interest and a breakout trend." He <a href="https://x.com/InvestingHaven/status/1852320937405989334">predicted</a> SHIB is "primed for a strong 2025."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41681345/dogecoin-killer-shiba-inu-burn-rate-explodes-254-078-higher-and-one-indicator-shows-a-90-r">&#8216;Dogecoin Killer&#8217; Shiba Inu Burn Rate Explodes 254,078% Higher And One Indicator Shows A 90% Rally Could Be Coming</a>
Why It Matters: Shibariumscan reported a rise in daily SHIB transactions from 4.68 million on Nov. 3 to 4.74 million on Nov. 4. Shibburn <a href="https://x.com/shibburn/status/1853633381621248439">data</a> shows the burn rate increasing by 5,929.2%. In the past 24 hours, 1.5 million SHIB coins were removed from the ecosystem.
Large transaction volume and daily active addresses declined by 6% and 10.7%, respectively, according to IntoTheBlock. Transactions greater than $100,000 are down from 147 to 114 in a single day.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41616239/shytoshi-kusama-touts-shiba-inu-lifetime-gains-of-33774726-we-still-have-far-to-go-and-muc">Shytoshi Kusama Touts Shiba Inu Lifetime Gains Of 33774726%: &#8216;We Still Have Far To Go And Much Work To Be Done&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SHIB

'Dogecoin Killer' Shiba Inu Up 3%: What Is Going On?

Scotiabank analyst George Farmer upgrades argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Sector Perform to Sector Outperform and raises the price target from $439 to $715.

Upgrades

ARGX

Scotiabank Upgrades argenx to Sector Outperform, Raises Price Target to $715

Earnings

Earnings Beats

Cummins Q3 2024 Adj. EPS $5.60 Beats $4.80 Estimate

<figure class="table"> 
<table>
<tbody>
<tr>
<td>Previous FY 2024 Guidance</td>
<td>Updated FY 2024 Guidance</td>
</tr>
<tr>
<td>Net Sales</td>
<td>$1.44 to $1.48 billion</td>
</tr>
<tr>
<td>Adjusted EBITDA1</td>
<td>$240 to $250 million</td>
</tr>
<tr>
<td>Free Cash Flow1</td>
<td>$100 to $120 million</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;

Guidance

HLMN

Hillman Solutions Revised Its 2024 Revenue Guidance To $1.455B-$1.485B (From $1.44B-$1.48B) Vs $1.467B Est.; Free Cash Flow To $100M-$115M (Vs. $100M-$120M Prior)

These monthly dividends, which will be payable pursuant to the table below, total $0.75 per share for the first quarter of 2025 and represent a 2.0% increase from the regular monthly dividends declared for the fourth quarter of 2024 and a 4.2% increase from the regular monthly dividends paid in the first quarter of 2024.

Dividends

MAIN

Main Street Declares Supplemental Dividend Of $0.30 Per Share Payable In December 2024; Boosts Regular Monthly Dividends To $0.25 Per Share For Each Of January, February And March 2025

CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.51 by 29.41 percent. This is a 100 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $124.75 million which beat the analyst consensus estimate of $117.13 million by 6.51 percent. This is a 17.84 percent increase over sales of $105.86 million the same period last year.

PMTS

CPI Card Q3 Adj $0.66 Beats $0.51 Estimate, Sales $124.75M Beat $117.13M Estimate

2024 Outlook:
Based on its current forecast, Cummins is maintaining its full-year 2024 revenue guidance to be in the range of down 3% to flat. EBITDA is expected to be approximately 15.5%; at the top end of the previous guidance of 15.0% to 15.5%.
Cummins plans to continue generating strong operating cash flow and returns for shareholders and is committed to our long-term strategic goal of returning 50% of operating cash flow back to shareholders. In the near term, we will focus on reinvesting for profitable growth, dividends and reducing debt.

Cummins Affirms FY24 Sales Guidance Of $33.04B-$34.06B Vs, $33.60B Estimate

2024 guidance is as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$950 million - $960 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Transaction costs</td>
<td colspan="1" rowspan="1">~16.0% of revenue</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$255 million to $265 million</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Payoneer Global Sees FY24 Revenue $950M-$960M (Prior $920M-$930M) Vs $928.71M Est.; Transaction Costs ~16.0% Of Revenue (Prior ~16.5%); Adjusted EBITDA $255M-$265M (Prior $225M-$235M)

2024&nbsp;Financial Outlook
Based on its current operating plans, Karyopharm has further narrowed its guidance for full year 2024 as follows:
<ul>
<li>Total revenue to be in the range of $145.0 million to $155.0 million as compared to the Company's prior guidance of $145.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.</li>
<li>U.S. XPOVIO net product revenue to be in the range of $110.0 million to $115.0 million as compared to the Company's prior guidance of $105.0 million to $120.0 million.</li>
<li>R&amp;D and selling, general and administrative (SG&amp;A) expenses to be in the range of $255.0 million to $265.0 million, which includes approximately $20.0 million estimated non-cash stock-based compensation expense, as compared to the Company's prior guidance of $250.0 million to $265.0 million.</li>
<li>The Company expects that its existing cash, cash equivalents and investments, the revenue it expects to generate from XPOVIO net product sales and its license agreements and ongoing disciplined expense management and cost saving measures, will be sufficient to fund its planned operations into the first quarter of 2026.</li>
</ul>

Biotech

Health Care

General

KPTI

Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M

Baird analyst Tristan Gerra maintains Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) with a Outperform and lowers the price target from $7 to $5.

NVTS

Baird Maintains Outperform on Navitas Semiconductor, Lowers Price Target to $5

LGI Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.54 by 16.14 percent. The company reported quarterly sales of $651.854 million which beat the analyst consensus estimate of $646.459 million by 0.83 percent. This is a 5.56 percent increase over sales of $617.539 million the same period last year.

LGIH

LGI Homes Q3 2024 GAAP EPS $2.95 Beats $2.54 Estimate, Sales $651.854M Beat $646.459M Estimate

Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is currently under investigation for potential tax fraud in France and the Netherlands. 
What Happened: The offices of the streaming giant were searched by investigators on Tuesday morning as part of a preliminary inquiry into alleged tax fraud and money laundering, reported Reuters.
The investigation, led by the French National Financial Prosecutor&#8217;s Office (PNF,) is focused on potential financial crimes and corruption. The probe, which began in November 2022, has led to searches at Netflix&#8217;s offices in central Paris and its European headquarters in Amsterdam.
A preliminary investigation in France does not automatically indicate that criminal charges will be filed or that a trial will occur.
See Also: <a href="https://www.benzinga.com/news/24/11/41703723/mark-cubans-million-dollar-advice-to-teens-if-i-were-16-again-id-start-this-lucrative-side-hustle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban&#8217;s Million-Dollar Advice To Teens: &#8216;If I Were 16 Again, I&#8217;d Start This Lucrative Side Hustle&#8217;</a>
Dutch authorities were simultaneously searching Netflix&#8217;s European headquarters in Amsterdam, according to the French judicial source. Neither Netflix France nor Netflix Netherlands have released a statement.
Netflix did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: In 2022, Netflix settled a tax dispute with Italy by paying 55.8 million euros ($60.78 million). The company, which opened its Paris office in 2020, produces most of its original films and series by working with third-party contractors.
This investigation comes at a time of significant change within Netflix. The company recently <a href="https://www.benzinga.com/news/24/10/41631621/netflix-restructures-leadership-bids-farewell-to-two-key-executives">restructured its leadership</a>, with the departure of two key executives, Rachel Whetstone, chief communications officer, and Dean Garfield, VP of public policy. This restructuring was part of a planned change announced by Co-CEO Ted Sarandos.
Price Action: Netflix stock, which has gained 61.26% so far this year, was down 0.2% during premarket trading on Tuesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41701405/dont-ever-use-this-word-around-mark-cuban-you-sound-stupid-because-youre-trying-to-sound-smart?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Don&#8217;t Ever Use This Word Around Mark Cuban: &#8216;You Sound Stupid &#8230; Because You&#8217;re Trying To Sound Smart&#8217;</a></li>
</ul>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Entertainment

Equities

Global

Markets

Tech

NFLX

Netflix In Hot Water As Tax Fraud Investigators Raid French, Dutch Offices: Report

CRGO

Freightos Welcomes Qantas Freight To WebCargo Platform, Enhancing Digital Booking Options Across Key Trans-Pacific Trade Routes

Keybanc analyst John Vinh maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Overweight and lowers the price target from $150 to $115.

SLAB

Keybanc Maintains Overweight on Silicon Laboratories, Lowers Price Target to $115

Hillman Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. The company reported quarterly sales of $393.300 million which beat the analyst consensus estimate of $387.780 million by 1.42 percent. This is a 1.41 percent decrease over sales of $398.943 million the same period last year.

Hillman Solutions Q3 2024 Adj. EPS $0.16, Inline, Sales $393.300M Beat $387.780M Estimate

LIND

Lindblad Expeditions Continues To See FY24 Tour Revenues Of $610M - $630M (Est $622.65M), Adjusted EBITDA  Of $88M - $98M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 13.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $38.78 million which beat the analyst consensus estimate of $37.79 million by 2.63 percent. This is a 7.70 percent increase over sales of $36.01 million the same period last year.

Karyopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate

Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) reported quarterly earnings of $5.86 per share which beat the analyst consensus estimate of $4.78 by 22.59 percent. This is a 27.67 percent increase over earnings of $4.59 per share from the same period last year. The company reported quarterly sales of $8.456 billion which beat the analyst consensus estimate of $8.294 billion by 1.96 percent. This is a 0.30 percent increase over sales of $8.431 billion the same period last year.

Cummins Q3 2024 GAAP EPS $5.86 Beats $4.78 Estimate, Sales $8.456B Beat $8.294B Estimate

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Olema Pharmaceuticals (OLMA – Research Report). The associated price tar...

Buy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic Collaborations

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on OLMA stock, giving a Buy rating today. Tyler Van Buren has given his Buy ra...

Buy Rating Affirmed: Promising Clinical Trial Results and Future Prospects for Olema Pharmaceuticals

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Olema Pharmaceuticals (OLMA – Research Report). The associated price ta...

Buy Rating for Olema Pharmaceuticals Based on Promising Clinical Data and Strategic Drug Positioning

Oppenheimer analyst Matthew Biegler maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of $30.0...

Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Naureen Quibri...

Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials

Olema Pharmaceuticals ( ($OLMA) ) has issued an update. Olema Pharmaceuticals has updated its corporate presentation with exciting developments in ...

Olema Pharmaceuticals Advances Breast Cancer Treatment Trials

Olema Pharmaceuticals announced results from three preclinical studies that will be presented during poster sessions at the 36th EORTC-NCI-AACR Sym...

Olema Oncology presents preclinical data on anti-tumor activity for OP-3136

Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar f...

Buy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline Synergy

Analyst Naureen Quibria of Capital One Financial assigned a Buy rating on Olema Pharmaceuticals (OLMA – Research Report), with a price target of $2...

Promising Potential of Olema Pharmaceuticals' Palazestrant and KAT6 Inhibitor Fuels Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price target at ...

Olema Pharmaceuticals' Promising KAT6 Inhibitor Program Justifies Buy Recommendation

OLMA

Press Releases

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Comments

Olema Pharmaceuticals

Vendite allo scoperto

Olema Pharmaceuticals (NASDAQ:OLMA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO